CD19 and systemic sclerosis: A phase-I randomised placebo-controlled trial assessing a humanised monoclonal antibody targeting CD19 (MEDI551, inebilizumab) found it effectively depleted B cells and plasma cells and appeared well tolerated in SSc (159).